marathon pharmaceuticals
FDA approves first treatment for Duchenne muscular dystrophy
February 10, 2017Medical Communications, Sales and Marketing Duchenne Muscular Dystrophy, FDA, marathon, marathon pharmaceuticals
The FDA has announced that it has approved Emflaza (deflazacort), developed by Marathon Pharmaceuticals. The treatment will arrive on the …
FDA accepts Marathon’s Duchenne drug for priority review
August 11, 2016Research and Development, Sales and Marketing Duchenne Muscular Dystrophy, FDA, deflazacort, marathon, marathon pharmaceuticals
Marathon Pharmaceuticals has announced that the US Food and Drug Administration (FDA) has accepted and granted a priority review for …
Marathon Pharma submits application for Duchenne muscular dystrophy drug to FDA
June 15, 2016Research and Development, Sales and Marketing FDA, duchenne, marathon pharmaceuticals
Marathon Pharmaceuticals has announced that it has submitted a New Drug Application (NDA) to the US Food and Drug Administration …
Latest content
FibroFind appoints Lee Borthwick as CEO
July 21, 2026
